Toward a molecular classification of colorectal cancer: The role of BRAF

Frontiers in Oncology

Volumn 3 NOV, Issue , 2013, Pages

  Thiel, Alexandra ^a,b   Ristimäki, Ari ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

BRAF; Colorectal cancer; Dabrafenib; Lynch syndrome; Microsatellite instability; V600E; V600K; Vemurafenib

Indexed keywords

B RAF KINASE; CETUXIMAB; DABRAFENIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NUTLIN 3; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; SORAFENIB; TRAMETINIB; VEMURAFENIB;

CANCER PROGNOSIS; CELL GROWTH; CELL INVASION; COLORECTAL CANCER; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; SIGNAL TRANSDUCTION; THERAPY RESISTANCE;

EID: 84891095143     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00281     Document Type: Short Survey

References (75)

1. Niault TS, Baccarini M. Targets of raf in tumorigenesis. Carcinogenesis (2010) 31:1165-74. doi:10.1093/carcin/bgp337
2. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 3:954-87.
3. Roskoski R Jr. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun (2010) 399:313-7. doi:10.1016/j.bbrc.2010.07.092
4. Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology (2013) 45:346-56. doi:10.1097/PAT.0b013e328360b61d
5. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer (2011) 104:392-8. doi:10.1038/sj.bjc.6606030
6. Kudchadkar R, Paraiso KH, Smalley KS. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J (2012) 18:124-31. doi:10.1097/PPO.0b013e31824b436e
7. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene (2009) 28:2119-23. doi:10.1038/onc.2009.73
8. Lawson AR, Tatevossian RG, Phipps KP, Picker SR, Michalski A, Sheer D, et al. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol (2010) 120:271-3. doi:10.1007/s00401-010-0693-y
9. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO: Classification of Tumours of the Digestive System, Fourth Edition. Lyon: IARC Press (2010).
10. McCourt CM, McArt DG, Mills K, Catherwood MA, Maxwell P, Waugh DJ, et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One (2013) 8:e69604. doi:10.1371/journal.pone.0069604
11. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol (2011) 122:11-9. doi:10.1007/s00401-011-0841-z
12. Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer (2013) 133:1624-30. doi:10.1002/ijc.28183
13. Affolter K, Samowitz W, Tripp S, Bronner MP. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer (2013) 52:748-52. doi:10.1002/gcc.22070
14. Sinicrope FA, Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, et al. Mutation-specific antibody detects mutant BRAF protein expression in human colon carcinomas. Cancer (2013) 119:2765-70. doi:10.1002/cncr.28133
15. Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol (2013) 37:1592-602. doi:10.1097/PAS.0b013e31828f233d
16. Thiel A, Heinonen M, Kantonen J, Gylling A, Lahtinen L, Korhonen M, et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch (2013). doi:10.1007/s00428-013-1470-9
17. Adackapara CA, Sholl LM, Barletta JA, Hornick JL. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology (2013) 63:187-93. doi:10.1111/his.12154
18. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 65:6063-9. doi:10.1158/0008-5472.CAN-05-0404
19. Mesteri I, Bayer G, Meyer J, Capper D, Schoppmann SF, von Deimling A, et al. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mod Pathol (2013). doi:10.1038/modpathol.2013.126
20. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF'and K-RAS-mutated colorectal cancer and implications for prognosis. Int JCancer (2010) 127:367-80. doi:10.1002/ijc.25042
21. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2010) 28:466-74. doi:10.1200/JCO.2009.23.3452
22. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol (2010) 21:2396-402. doi:10.1093/annonc/mdq258
23. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2012) 18:890-900. doi:10.1158/1078-0432.CCR-11-2246
24. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol (2012) 36:744-52. doi:10.1097/PAS.0b013e31824430d7
25. Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum (2012) 55:128-33. doi:10.1097/DCR.0b013e31823c08b3
26. Eklöf V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer (2013) 108:2153-63. doi:10.1038/bjc.2013.212
27. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut (2012) 61:847-54. doi:10.1136/gutjnl-2011-300865
28. Soreide K, Nedrebo BS, Soreide JA, Slewa A, Korner H. Lymph node harvest in colon cancer: influence of microsatellite instability and proximal tumor location. World J Surg (2009) 33:2695-703. doi:10.1007/s00268-009-02554
29. Eveno C, Nemeth J, Soliman H, Praz F, de The H, Valleur P, et al. Association between a high number of isolated lymph nodes in T1 to T4 N0M0 colorectal cancer and the microsatellite instability phenotype. Arch Surg (2010) 145:12-7. doi:10.1001/archsurg.2009.224
30. Berg M, Guriby M, Nordgard O, Nedrebo BS, Ahlquist TC, Smaaland R, et al. Influence of microsatellite instability, KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers. Mol Med (2013). doi:10.2119/molmed.2013.00049
31. Peeters M, Oliner K, Parker A, Siena S, Van Cutsem E, Huang J, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase 3 study of metastatic colorectal cancer. Clin Cancer Res (2013) 19:1902-12. doi:10.1158/1078-0432.CCR-12-1913
32. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 105:1151-6. doi:10.1093/jnci/djt173
33. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol (2009) 27:5931-7. doi:10.1200/JCO.2009.22.4295
34. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 14:3408-15. doi:10.1158/1078-0432.CCR-07-1489
35. Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol (2013) 108:1785-93. doi:10.1038/ajg.2013.292
36. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 7:e47054. doi:10.1371/journal.pone.0047054
37. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 26:5705-12. doi:10.1200/JCO.2008.18.0786
38. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 11:753-62. doi:10.1016/S1470-2045(10)70130-3
39. Yuan ZX, Wang XY, Qin QY, Chen DF, Zhong QH, Wang L, et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One (2013) 8:e65995. doi:10.1371/journal.pone.0065995
40. Garcia-Alfonso P, Salazar R, Garcia-Foncillas J, Musulen E, Garcia-Carbonero R, Paya A, et al. Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish society of pathology (SEAP) and the Spanish society of medical oncology (SEOM). Clin Transl Oncol (2012) 14:726-39. doi:10.1007/s12094-012-0856-5
41. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 46:1997-2009. doi:10.1016/j.ejca.2010.03.036
42. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 29:2011-9. doi:10.1200/JCO.2010.33.5091
43. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer (2012) 48:1466-75. doi:10.1016/j.ejca.2012.02.057
44. Oliner K, Douillard J, Siena S, Tabernero J, Burkes R, Barugel M, et al. Evaluation of KRAS, NRAS, and BRAF mutations in PRIME: panitumumab with FOLFOX4 as first-line treatment in metastatic colorectal cancer (mCRC). Ann Oncol (2013) 24(Suppl 4):iv23-4. doi:10.1093/annonc/mdt201.31
45. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol (2011) 29:1261-70. doi:10.1200/JCO.2010.30.1366
46. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 62:812-23. doi:10.1136/gutjnl-2012-304356
47. Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S, et al. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National society of genetic counselors and the collaborative group of the Americans on inherited colorectal cancer joint practice guideline. J Genet Couns (2012) 21:484-93. doi:10.1007/s10897-011-9465-7
48. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 308:1555-65. doi:10.1001/jama.2012.13088
49. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet (2012) 49:151-7. doi:10.1136/jmedgenet-2011-100714
50. Mandala M, Voit C. Targeting BRAF in melanoma: biological and clinical challenges. Crit Rev Oncol Hematol (2013) 87:239-55. doi:10.1016/j.critrevonc.2013.01.003
51. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 27:2823-30. doi:10.1200/JCO.2007.15.7636
52. Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2013) 31:373-9. doi:10.1200/JCO.2012.42.1529
53. Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res (2013) 19:4326-34. doi:10.1158/1078-0432.CCR-13-0779
54. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 359:378-90. doi:10.1056/NEJMoa0708857
55. Lo RS. Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res (2012) 22:945-7. doi:10.1038/cr.2012.78
56. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol (2010) 28(Suppl):3534.
57. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res (2012) 72:779-89. doi:10.1158/0008-5472.CAN-11-2941
58. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 2:227-35. doi:10.1158/2159-8290.CD-11-0341
59. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 487:500-4. doi:10.1038/nature11183
60. Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 2:336-46.
61. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 106:20411-6. doi:10.1073/pnas.0905833106
62. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 468:973-7. doi:10.1038/nature09626
63. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 468:968-72. doi:10.1038/nature09627
64. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 140:209-21. doi:10.1016/j.cell.2009.12.040
65. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 480:387-90. doi:10.1038/nature10662
66. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 71:2750-60. doi:10.1158/0008-5472.CAN-10-2954
67. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 18:683-95. doi:10.1016/j.ccr.2010.11.023
68. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res (2013) 19:5749-57. doi:10.1158/1078-0432.CCR-13-0661
69. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3:ra84. doi:10.1126/scisignal.2001148
70. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 483:100-3. doi:10.1038/nature10868
71. Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcala A, Chen YE, et al. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppress melanoma viability and tumor growth. Clin Cancer Res (2013) 19:4383-91. doi:10.1158/1078-0432.CCR-13-0074
72. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2013) 19:657-67. doi:10.1158/1078-0432.CCR-11-1446
73. Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res (2013) 19:2688-98. doi:10.1158/1078-0432.CCR-12-2556
74. Rad R, Cadinanos J, Rad L, Varela I, Strong A, Kriegl L, et al. A genetic progression model of braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell (2013) 24:15-29. doi:10.1016/j.ccr.2013.05.014
75. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 367:1694-703. doi:10.1056/NEJMoa1210093